{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:47:08Z","timestamp":1765057628192,"version":"3.44.0"},"reference-count":27,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,9,25]]},"abstract":"<jats:p>Plasmablastic lymphoma (PBL) is an aggressive form of non-Hodgkin\u2019s lymphoma (NHL) classically seen in patients infected with the human immunodeficiency virus, but can also be seen in other immunocompromised states such as transplant recipients, autoimmune diseases and the elderly. PBL is generally associated with a poor prognosis despite chemotherapy. There is evidence supporting the use of bortezomib in combination with standard chemotherapy to achieve durable responses in patients with PBL. We describe a patient with acquired immunodeficiency syndrome who presented with rectal pain and bright red blood per rectum. He was diagnosed with stage IVA PBL with anorectal, nodal, calvarial and hepatic involvement. Along with highly active antiretroviral therapy, he was treated with six cycles of dose adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) plus bortezomib resulting in durable complete remission 30 months after diagnosis.<\/jats:p>","DOI":"10.1136\/bcr-2017-222063","type":"journal-article","created":{"date-parts":[[2017,10,9]],"date-time":"2017-10-09T09:10:54Z","timestamp":1507540254000},"page":"bcr-2017-222063","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma"],"prefix":"10.1136","volume":"2017","author":[{"given":"Nivedita","family":"Arora","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA"},{"name":"Parkland Health and Hospital System, Dallas, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjun","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA"},{"name":"Parkland Health and Hospital System, Dallas, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navid","family":"Sadeghi","sequence":"additional","affiliation":[{"name":"Parkland Health and Hospital System, Dallas, Texas, USA"},{"name":"Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,10,9]]},"reference":[{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-567479"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s12185-016-2082-3","article-title":"Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases","volume":"104","author":"Koizumi","year":"2016","journal-title":"Int J Hematol"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.3","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835e069d"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.4","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/annonc\/mdw684","article-title":"Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group","volume":"28","author":"Tchernonog","year":"2017","journal-title":"Ann Oncol"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.5","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.5858\/arpa.2016-0232-RA","article-title":"Plasmablastic lymphoma: a review of clinicopathologic features and differential diagnosis","volume":"140","author":"Harmon","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.6","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0163-z"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.7","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3892\/or.2015.3808","article-title":"Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases","volume":"33","author":"Liu","year":"2015","journal-title":"Oncol Rep"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.03.008"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.9","unstructured":"\u00a0NCCN clinical practice guidelines in oncology. Non-Hodgkin\u2019s lymphomas. 2014 https:\/\/www.nccn.org\/about\/nhl.pdf"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.10","doi-asserted-by":"crossref","first-page":"2014064","DOI":"10.4084\/mjhid.2014.064","article-title":"Current knowledge on HIV-associated plasmablastic lymphoma","volume":"6","author":"Bibas","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/MCP.0000000000000384","article-title":"Primary effusion lymphoma: current concepts and management","volume":"23","author":"Arora","year":"2017","journal-title":"Curr Opin Pulm Med"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.12","doi-asserted-by":"publisher","DOI":"10.1177\/2040620716648566"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.13","first-page":"7","article-title":"Bortezomib in plasmablastic lymphoma: a case report and review of the literature","volume":"36","author":"Saba","year":"2013","journal-title":"Onkologie"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.14","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.074"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.0038"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01235.x"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.06.023"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.18","first-page":"443","article-title":"HIV-negative plasmablastic lymphoma attaining sustained remission with bortezomib-combined dose-adjusted EPOCH therapy","volume":"58","author":"Kobayashi","year":"2017","journal-title":"Rinsho Ketsueki"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.19","first-page":"290","article-title":"[Clinical characteristics and survival analysis of eight cases HIV-negative plasmablastic lymphoma]","volume":"38","author":"Han","year":"2017","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.20","first-page":"1","article-title":"Bortezomib, ifosfamide, carboplatin, and etoposide in a patient with HIV-negative relapsed plasmablastic lymphoma","volume":"2016","author":"Akce","year":"2016","journal-title":"Case Rep Hematol"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.21","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00277-016-2601-6","article-title":"Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma","volume":"95","author":"Fedele","year":"2016","journal-title":"Ann Hematol"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.22","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/ejh.12732","article-title":"Long-term remission in a case of plasmablastic lymphoma treated with COMP (cyclophosphamide, liposomal doxorubicin, vincristine, prednisone) and bortezomib","volume":"96","author":"Cencini","year":"2016","journal-title":"Eur J Haematol"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40364-015-0053-0","article-title":"A striking response of plasmablastic lymphoma of the oral cavity to bortezomib: a case report","volume":"3","author":"Hirosawa","year":"2015","journal-title":"Biomark Res"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.24","doi-asserted-by":"crossref","unstructured":"Fernandez-Alvarez R , Gonzalez-Rodriguez AP , Rubio-Castro A , et al . Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients. Leuk Lymphoma 2015.doi:10.3109\/10428194.2015.1050666","DOI":"10.3109\/10428194.2015.1050666"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.25","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bjh.13300","article-title":"Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma","volume":"169","author":"Castillo","year":"2015","journal-title":"Br J Haematol"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.03.002"},{"key":"2025082804092365000_2017.oct07_1.bcr-2017-222063.27","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12286"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-222063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:09:37Z","timestamp":1756379377000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-222063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,9]]},"references-count":27,"alternative-id":["10.1136\/bcr-2017-222063"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-222063","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2017,10,9]]}}}